Catalog No.
Product Name
Application
Product Information
Citations
-
Octamer Peptide
OVA Peptide (257-264) is an octameric peptide epitope derived from ovalbumin that is specifically presented by the class I major histocompatibility complex (MHC) molecule H-2Kb. This peptide is crucial for T cell recognition and activation in immunological studies. It has applications in the development of immunotherapies, vaccine research, and studies focusing on T cell responses. -
Bioactive Peptide
OVA-Q4 Peptide is a bioactive peptide that serves as a variant of the ovalbumin-derived agonist peptide (SIINFEKL). It is recognized as a class I (Kb)-restricted peptide epitope presented by the H-2Kb major histocompatibility complex in mice. This peptide is instrumental in immunological research, particularly in studies involving T cell activation and antigen presentation. OVA-Q4 is valuable for applications in vaccine development and cellular immune response assessment. -
Antigen Peptide
OVA(250-264) is an antigenic peptide derived from ovalbumin, targeting the class I MHC molecule H-2Kb. This peptide has been shown to significantly enhance the generation and infiltration of antigen-specific CD8+ T cells when used in conjunction with αMSLN (anti-MSLN antibody), thus improving antitumor efficacy in orthotopic models of pancreatic cancer. OVA(250-264) serves as a valuable tool for the development of neoantigen vaccines in immunotherapy research focused on pancreatic cancer. -
HLA-DR Binding Epitope
PADRE peptide is a pan-HLA-DR binding epitope that functions as an immunostimulant by binding to the peptide-binding groove of MHC class II molecules, facilitating the activation of CD4+ T cells. This leads to enhanced anti-tumor immune responses, inhibition of tumor growth, and prolonged survival in model systems. PADRE peptide is effective in increasing the frequency of E7-specific CD8+ T cells and improving therapeutic outcomes when combined with E7 peptide-based vaccines and poly (I:C). It is suitable for research applications in various tumor models, including melanoma, glioblastoma, and cervical cancer. -
Bioactive Peptide
CMV pp65(13-27) is a bioactive peptide derived from amino acid residues 13 to 27 of the 65 kDa lower matrix phosphoprotein of human cytomegalovirus. This peptide encompasses a nine-amino-acid sequence (LGPISGHVL) that aligns with the consensus binding motif of the major histocompatibility complex H2-Dd T-cell epitope. It is utilized in immunological research, particularly for the study of T-cell responses and the development of cytomegalovirus vaccines. -
Peptide
MOG (89-113), human is a peptide derived from the myelin oligodendrocyte glycoprotein, which plays a critical role in myelin sheath formation and stability. This peptide fragment is utilized in research applications related to demyelinating diseases, including multiple sclerosis, where it serves as a target for studying immune responses and T cell activation. Its role in the modulation of inflammation makes it a valuable tool for understanding neuroinflammatory processes. -
WT1 Peptide
WT1 126-134 peptide is a peptide derived from the Wilms' tumor oncogene protein (RMFPNAPYL) that targets HLA-A0201. This peptide is known to induce cytotoxic CD8 T cells, which are capable of identifying and eliminating WT1-positive tumor cells. Additionally, WT1 126-134 peptide forms highly stable complexes with H-2Db (mouse) or HLA-A0201 (human), demonstrating a strong affinity (Kd = 0.2 nM) for humanized monoclonal antibodies (IgG1). It is applicable in immunotherapy as a vaccine for T cell activation or as a target for antibody development. -
Nucleoprotein Peptide
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide specifically derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). This peptide interacts with MHC class I molecules, facilitating the presentation to CD8+ T cells and promoting the activation of cytotoxic T lymphocytes (CTLs). It is particularly valuable in research focused on CTL vaccine development for infectious diseases, including Ebola virus, enhancing understanding of immune responses in viral infections. -
Polypeptide
MBP (111-129) is a polypeptide that represents an immunodominant epitope cluster restricted by HLA-DRB1*0401. This compound functions as an antagonist for the HD4-1C2 T cell receptor and as an agonist for the MS2-3C8 T cell receptor. MBP (111-129) is valuable for research in multiple sclerosis and T cell biology, providing insights into immune responses and potential therapeutic interventions. -
HLA-B7-Derived Peptide
Allotrap 07 is a synthetic peptide derived from residues 75-84 of the HLA-B7 molecule, a class I major histocompatibility complex (MHC) protein. This peptide is known for its ability to promote donor-specific tolerance in rat cardiac allografts when used in conjunction with Cyclosporin A, leading to a significant extension of graft survival. Allotrap 07 is a valuable tool for researchers exploring mechanisms of immune tolerance and transplant biology. -
MHC Peptide
SEIDLILGY is a nonapeptide that acts as a ligand for major histocompatibility complex class I (MHC) molecules, derived from mouse sources. This compound is primarily used to stimulate sensory neurons expressing the vomeronasal receptor V2rf2, facilitating studies in neural signaling and sensory processing. Its unique properties make it an invaluable tool for research in neurobiology and immunology. -
Melanoma Antigen-Derived Peptide
VLPDVFIRCV is a melanoma antigen-derived peptide that targets MHC-I class molecules. It has been shown to induce cytotoxic T lymphocytes (CTLs) capable of specifically lysing T2 cells pre-loaded with this peptide in chromium release assays. While VLPDVFIRCV does not activate immune responses against natural tumor cells, it is valuable for vaccine design research and studies focused on immune modulation in melanoma. -
HLA-A*0201-binding Peptide
Adipophilin-derived peptide is an HLA-A*0201-binding peptide that plays a crucial role in immune recognition and response. This peptide is particularly relevant in cancer research, as it may facilitate the study of tumor-associated antigens and their interactions with the immune system. Its application in immunotherapy and vaccine development makes it a valuable reagent for advancing cancer immunology studies. -
Antigenic Peptide
TP53 neoepitope is a high-affinity antigenic peptide that targets HLA-A molecules. It is designed to elicit CD8+ T cell-mediated cytotoxicity against tumor cells harboring TP53 mutations, specifically hotspot mutations such as R175H and R273H. This peptide is promising for research applications in the immunotherapy of solid tumors with TP53 alterations, providing insights into potential therapeutic interventions targeting mutant TP53 pathways. -
Inhibitor Of The Binding Of DQ8 Peptide To MHC Class II Molecule
D-α-Methyl DOPA is an inhibitor of the binding of DQ8 peptide to MHC class II molecules. By occupying a pocket in the DQ8 peptide binding groove, D-α-Methyl DOPA disrupts the presentation of DQ8 peptides to CD4+ T cells. This inhibition may play a role in modulating the immune response, potentially slowing the development or progression of type 1 diabetes and celiac disease. This compound is valuable in immunological research focused on T cell activation and autoimmune disease mechanisms. -
Peptide
MUC5AC motif peptide is a 16-amino acid fragment derived from mucin 5, targeting mucin-related signaling pathways. This peptide plays a crucial role in modulating mucosal immunity and has applications in studying respiratory diseases and gastrointestinal disorders. Its capacity to influence cellular adhesion and immune responses makes it a valuable tool for research in mucosal biology and therapeutic interventions. -
Polypeptide
YIGSR (Laminin Fragment 929-933) is a polypeptide that serves as an inhibitor of tumor growth and metastasis in leukemia cells. It exhibits specific binding to the 67kDa laminin receptor, influencing the expression of endothelial nitric oxide synthase (eNOS) in endothelial cells. This peptide is valuable for research focused on leukemia and related pathophysiological mechanisms. -
SPSB2-iNOS Inhibitor
SPSB2-iNOS inhibitory cyclic peptide-1 is a potent inhibitor targeting the interaction between SPSB2 and inducible nitric oxide synthase (iNOS), exhibiting a binding affinity (KD) of 4.4 nM. This cyclic peptide demonstrates resistance to proteolytic degradation by pepsin, trypsin, and α-chymotrypsin, ensuring stability in biological environments. Additionally, it maintains stability in human plasma and oxidative conditions, making it a valuable tool for studying iNOS-related pathways in inflammation and other biological processes. -
Control Peptide
Tat-NR2Baa is a control peptide designed to evaluate the specificity of Tat-NR2B9c. This inactive variant features a double-point mutation in the COOH terminal tSXV motif, which prevents binding to the postsynaptic density protein PSD-95. While it retains structural similarity to Tat-NR2B9c, Tat-NR2Baa does not disrupt the PSD-95/NMDAR interaction. It serves as a valuable tool in studies investigating the roles of PSD-95 in NMDAR signaling pathways and related neurophysiological research. -
NO Synthase Activator
eNOS pT495 decoy peptide is a specific inhibitor designed to disrupt the phosphorylation at T495, thereby promoting eNOS uncoupling and preventing mitochondrial redistribution. This peptide serves as a valuable tool in the investigation of nitric oxide synthase activation, particularly in studies related to ventilator-induced lung injury and associated pathophysiological mechanisms. Its role in modulating eNOS activity makes it essential for exploring therapeutic approaches in respiratory and cardiovascular research. -
Antitumor Peptide
YIGSR-Lys(N3) is an antitumor peptide that targets cellular interactions with laminin I through the inhibition of the 67-kDa laminin-binding protein, effectively hindering the growth and metastasis of leukemic cells. Additionally, it modulates the shear-induced expression of endothelial nitric oxide synthase in laminin cells. This compound serves as a click chemistry reagent, featuring an azide group that participates in copper-catalyzed azide-alkyne cycloaddition and strain-promoted alkyne-azide cycloaddition reactions with alkyne-containing or DBCO/BCN-bearing molecules, respectively. Its versatile reactivity makes it valuable for research in both cancer biology and chemical biology applications. -
SPSB2-iNOS Inhibitor
SPSB2-iNOS inhibitory cyclic peptide-2 is a selective inhibitor of the interaction between SPSB2 and inducible nitric oxide synthase (iNOS), exhibiting a binding affinity with a KD of 21 nM. This cyclic peptide is both reduction-resistant and oxidatively stable, making it suitable for various biological assays. Its ability to inhibit SPSB2-iNOS interactions positions it as a valuable tool in research focused on nitric oxide signaling and related pathophysiological processes. -
SPSB2-iNOS Inhibitor
SPSB2-iNOS inhibitory cyclic peptide-3 is a selective inhibitor targeting the interaction between SPSB2 and inducible nitric oxide synthase (iNOS). This compound binds to the SPSB2 site on iNOS with a dissociation constant (KD) of 7 nM. It demonstrates significant biological activity in modulating nitric oxide production and has potential applications in studies related to inflammation and oxidative stress. -
Antidepressant Peptide
Tat-SERT-15C is an antidepressant peptide that modulates the serotonin transporter (SERT) and nitric oxide synthase (nNOS) interaction. This peptide decreases the SERT-nNOS complex, leading to enhanced SERT expression. Tat-SERT-15C has demonstrated efficacy in reversing depression-like behaviors induced by chronic unpredictable mild stress, making it a valuable tool for research into the mechanisms of depression and potential therapeutic interventions. -
Thrombin Peptide
TP508 is a 23-amino acid nonproteolytic thrombin peptide that selectively targets the receptor-binding domain of thrombin. It activates endothelial nitric oxide synthase (eNOS) and promotes nitric oxide production in human endothelial cells, facilitating enhanced endothelial cell activation and stem cell recruitment. This molecule is of significant interest for applications in tissue revascularization and regenerative medicine research. -
FOXP3 Inhibitor
Peptide P60 is a potent FOXP3 inhibitor that disrupts the nuclear translocation of FOXP3, thereby decreasing its regulatory effects on NF-κB and NFAT signaling pathways. This action inhibits the immunosuppressive capabilities of regulatory T cells, facilitating the proliferation and activation of effector T cells. Experimental studies have shown that Peptide P60 can induce lymphoproliferative autoimmune syndrome in neonatal ICR mice and diminish the population of CD4+CD25+Foxp3+ T cells in the spleen. Additionally, it enhances the efficacy of peptide vaccines and recombinant adenovirus-based vaccines, making it valuable for research in tumor immunology, viral infections, and autoimmune conditions. -
Osteopontin-derived Peptide
SVVYGLR is an osteopontin-derived peptide that primarily promotes fibroblast differentiation into myofibroblast-like cells and enhances type III collagen production by cardiac fibroblasts. It effectively activates adhesion, migration, and tubule formation in endothelial cells, thereby facilitating angiogenesis and wound healing processes. Additionally, SVVYGLR supports the migration of dermal fibroblasts and keratinocytes, making it a valuable reagent for research in angiogenesis, dermal wounds, and bone regeneration studies. -
PSMA Targeting Peptide
PSMA Targeting Peptide (GRFLTGGTGRLLRIS) is designed to specifically bind to Prostate-Specific Membrane Antigen (PSMA) on prostate cancer cells. This peptide facilitates the targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs, enhancing the efficacy of RNA interference in therapeutic applications. The peptide can be modified by adding polyarginine sequences at the C-terminus, and when labeled with FITC through an aminohexanoic acid linker at the N-terminus, it allows for precise tracking of PSMA interactions in cellular contexts. -
Antioxidant Peptide
Antioxidant Peptide A is a short peptide featuring alternative aromatic or sulfur-containing amino acids, which facilitate its robust radical scavenging capabilities. This peptide exhibits significant antioxidant activity, demonstrating potential in mitigating oxidative stress within cancer cells. It serves as a valuable tool for research applications focused on oxidative damage and cancer biology. -
Anxiolytic Agent
δ-Sleep Inducing Peptide is a neuropeptide that functions as an anxiolytic agent. It exhibits antioxidant properties and plays a critical role in the modulation of sleep and anxiety-related behaviors. This compound is primarily used in research exploring neurobiology, sleep regulation, and mental health disorders. -
9-mer Peptide Probe
AE105 is a 9-mer peptide probe that specifically targets the urokinase-type plasminogen activator receptor (uPAR). It exhibits high-affinity binding to the uPA-binding cavity of uPAR, making it a valuable tool for investigating uPAR-related signaling pathways. This peptide probe is particularly useful in cancer research, aiding in the exploration of tumor progression and metastasis mechanisms. -
Bioactive Peptide
Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide that targets CD36 and angiostatin. This peptide disrupts cell adhesion and migration by interfering with the interaction between cells and the extracellular matrix. Additionally, it demonstrates the capability to inhibit platelet aggregation and exhibits anti-tumor properties, particularly against colon cancer. Its applications encompass studies of cell adhesion dynamics, platelet function, and potential therapeutic strategies in oncology. -
FKBPL Peptide
AD 01 is a 24-amino acid peptide derived from FKBPL (FK506-binding protein like), targeting the CD44 receptor to exert significant anti-angiogenic effects. By binding to CD44, AD 01 effectively inhibits tumor cell migration in a manner dependent on this receptor. This peptide is valuable for research applications focused on cancer biology, particularly in studies related to angiogenesis and tumor metastasis. -
GPR110 Agonist
GPR110 peptide agonist P12 is an agonist targeting the GPR110 receptor. This peptide significantly enhances the initial rate of G protein GTPγS binding stimulated by GPR110, effectively mimicking natural ligands. By inducing dissociation between the receptor's extracellular domain and its seven transmembrane domains, P12 exposes the β-strand-13/stalk region of the 7TM domain, facilitating G protein signaling activation. This compound is valuable for research into developmental disorders and cancers associated with GPR110 pathways. -
CD63-binding Peptide
CP05 is a CD63-binding peptide that specifically interacts with the exosome surface marker CD63. This interaction facilitates the anchoring of exosomes to target tissues, enhancing in vivo delivery of exosomal payloads. CP05 is useful in research applications focused on drug delivery, therapeutic targeting, and the study of exosome biology. -
Analogue of the Glycopeptide
Glycotriosyl glutamine is a synthetic analogue of Glycopeptide that targets glomerular structures in kidney cells. This compound has been shown to induce focal glomerulonephritis (FGN) in animal models, specifically resulting in the formation of myeloid bodies within podocyte epithelial cells. Its unique properties make it a valuable tool for investigating nephritogenic mechanisms and kidney disease pathology. -
CD36 Peptide
CD36 Peptide P (139-155), Cys conjugated targets the CD36 protein and serves as a crucial tool for studying its function. This Cys-conjugated peptide is effective in inhibiting the immunoadsorption of CD36 by the OKM5 antibody, making it valuable for research applications focused on immune responses and metabolic processes. The peptide can aid in the investigation of CD36-related pathways and its role in various biological contexts. -
Bioactive Peptide
Tumour-associated MUC1 epitope is a bioactive peptide targeting the MUC1 mucin, a type I transmembrane glycoprotein characterized by a highly glycosylated extracellular domain composed of repeated 20 amino acid units. This epitope is overexpressed on the surface of various human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma. Its frequent upregulation in cancer cells renders the MUC1 epitope a valuable target for the development of immunotherapeutic strategies, facilitating advancements in cancer treatment research. -
CD36 Peptide
CD36 Peptide P (93-110), Cys conjugated specifically targets CD36, a multifunctional receptor involved in cellular adhesion and lipid metabolism. This peptide has been shown to block the binding of CD36 to immobilized thrombospondin, thereby providing valuable insights into CD36-mediated pathways. Additionally, it partially inhibits collagen-induced platelet aggregation, making it useful for research applications related to cardiovascular function and cell signaling. -
Antigen Peptide Segment
[Gln144]-PLP (139-151) is an experimental antigen peptide segment designed to engage T-cell receptors (TCR) and activate T cells. This activation plays a crucial role in examining the immune response to both autoantigens and cross-reactive non-autoantigens. Its applications extend to the investigation of the underlying mechanisms involved in the regulation of autoimmune diseases, providing insights into potential therapeutic approaches. -
p32-targeting Peptide
LinTT1 peptide is a tumor-penetrating peptide that specifically targets the p32 (gC1qR) receptor. This peptide demonstrates enhanced cellular uptake in peritoneal carcinoma (PC) cells, facilitating mitochondrial entry and promoting targeted drug delivery. When conjugated with iron oxide nanoworms, LinTT1 forms a nanocarrier that significantly enhances tumor penetration and targeting in vivo. Additionally, when combined with the pro-apoptotic peptide [D(KLAKLAK)2], LinTT1-functionalized nanocarriers exhibit pronounced tumor suppression in mouse models of peritoneal cancer, highlighting its potential as an effective carrier in cancer research. -
VCAM1 Binding Peptide
VCAM1 Binding Peptide is designed to specifically bind to Vascular Cell Adhesion Molecule 1 (VCAM1). This peptide, with the sequence VHPKQHRGGSKGC, serves as a valuable tool for investigating VCAM1's role in cellular adhesion and inflammatory processes. It is commonly used in research applications focused on vascular biology, immunology, and disease models related to cardiovascular conditions. -
FAP-binding peptide
Rofapitide tetraxetan is a highly selective fibroblast activation protein (FAP)-binding peptide, exhibiting a mean IC50 of 2.7 nM for FAP binding. This compound demonstrates significant antitumor activity and can be effectively labeled with radionuclides for use in diagnostic imaging. Its specific targeting of FAP makes it a valuable tool for research applications in cancer diagnosis and therapy. -
FAP-Targeting Peptide
3BP-4089 is a potent fibroblast activation protein (FAP)-targeting peptide designed for theranostic applications. This peptide effectively facilitates the targeting of tumor microenvironments, allowing for enhanced imaging and therapeutic strategies. Coupling 3BP-4089 with radionuclides supports its utility in tumor diagnosis and advanced cancer research. -
Galectin-3 Binding Peptide
G3-C12 is a galectin-3 binding peptide with a Kd of 88 nM, designed to selectively target galectin-3. This compound demonstrates significant anticancer activity, making it a valuable tool in cancer research. G3-C12 can be utilized in studies investigating the role of galectin-3 in tumor progression and metastasis, as well as in the development of novel therapeutic strategies. -
GPVI Antagonist
Pep-10L peptide is a glycoprotein VI (GPVI) antagonist that exhibits inhibition with Ki values of 180, 225, and 179 μM for CPR, GPO-1, and Type 1 collagen, respectively. This peptide demonstrates significant anti-thrombotic effects, making it valuable for research in platelet function and thrombus formation. Pep-10L is useful in studies aimed at exploring GPVI signaling pathways and developing therapies for thrombotic diseases. -
GPC3 Targeting Peptide
GPC3 Targeting Peptide 1 is a synthetic peptide that selectively binds to glypican-3 (GPC3) with a dissociation constant (Kd) of 0.23 nM. This high-affinity interaction makes it a valuable tool for GPC3-related research, including studies on cancer biology, particularly in liver cancer, and potential therapeutic applications targeting GPC3-expressing tumors. The peptide's specificity for GPC3 facilitates the exploration of mechanisms underlying tumorigenesis and enables the development of targeted drug delivery systems. -
Bioactive Peptide
IGRP(206-214) is a bioactive peptide derived from the residues 206-214 of the murine islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). This peptide specifically targets T cells associated with proinsulin and IGRP, playing a pivotal role in the induction of diabetes in non-obese diabetic (NOD) mice models. IGRP(206-214) is valuable for research applications focused on autoimmune diabetes and T cell-mediated responses. -
KRAS G12V Peptide
KRAS G12V Peptide is a synthetic peptide derived from the Kirsten rat sarcoma virus (KRAS) gene featuring the oncogenic G12V mutation. This peptide is known to stimulate immune responses, including the secretion of IFN-γ and enhanced cytotoxic activity. KRAS G12V Peptide serves as a valuable tool for investigating immune responses to KRAS G12V-mutant tumors, facilitating research in cancer immunotherapy and tumor biology. -
Peptide Segment
MSP-1 (20-39) is a peptide segment that stimulates the production of interferon-gamma (IFN-γ). This functionality positions MSP-1 (20-39) as a potential candidate for malaria vaccine development. It serves as a valuable tool for research in malaria and immunology, enabling studies into immune responses and disease mitigation strategies.
